Skip to main content

Table 6 Pairwise hazard ratios and 95% credible intervals of interventions licensed in Europe based on RCT evidence as well as all 5 matches connecting the separate networks satisfying the similarity threshold

From: The use of single armed observational data to closing the gap in otherwise disconnected evidence networks: a network meta-analysis in multiple myeloma

  dara+bor + dex carf+len + dex ixa + len + dex elo + len + dex carf+dex bor + PLD len + dex thal+bor + dex bor + dex + pan pom + dex bor bor + dex
dara+len + dex 0.56 (0.35,0.87) 0.51 (0.37,0.70) 0.49 (0.36,0.67) 0.44 (0.32,0.62) 0.43 (0.28,0.65) 0.35 (0.22,0.53) 0.34 (0.27,0.43) 0.33 (0.18,0.62) 0.30 (0.20,0.44) 0.29 (0.19,0.42) 0.25 (0.17,0.37) 0.22 (0.15,0.32)
dara+bor + dex   0.91 (0.58,1.42) 0.88 (0.56,1.36) 0.80 (0.50, 1.24) 0.77 (0.56,1.06) 0.62 (0.37,1.06) 0.61 (0.40,0.90) 0.60 (0.33,1.08) 0.54 (0.39,0.74) 0.52 (0.32,0.83) 0.45 (0.28,0.72) 0.39 (0.30,0.50)
carf+len + dex    0.97 (0.73,1.27) 0.87 (0.64,1.18) 0.85 (0.56,1.29) 0.68 (0.44,1.04) 0.67 (0.55,0.82) 0.66 (0.35,1.20) 0.59 (0.41,0.85) 0.57 (0.39,0.83) 0.49 (0.34,0.71) 0.43 (0.29,0.61)
ixa + len + dex     0.90 (0.67,1.22) 0.88 (0.58,1.30) 0.70 (0.47,1.07) 0.69 (0.57,0.84) 0.68 (0.37,1.24) 0.61 (0.43,0.87) 0.59 (0.41,0.85) 0.51 (0.36,0.72) 0.44 (0.31,0.63)
elo + len + dex      0.97 (0.63,1.50) 0.78 (0.51,1.22) 0.77 (0.61,0.96) 0.75 (0.41,1.39) 0.68 (0.47,0.99) 0.65 (0.44,0.96) 0.56 (0.39,0.82) 0.49 (0.33,0.72)
carf+dex       0.80 (0.49,1.32) 0.79 (0.55,1.13) 0.78 (0.44,1.37) 0.70 (0.53,0.91) 0.67 (0.43,1.06) 0.58 (0.37,0.79) 0.50 (0.42,0.60)
bor + PLD        0.98 (0.68,1.42) 0.97 (0.49,1.89) 0.87 (0.55,1.37) 0.83 (0.56,1.24) 0.72 (0.58,0.91) 0.63 (0.39,0.99)
len + dex         0.98 (0.55,1.74) 0.88 (0.66,1.20) 0.85 (0.62,1.16) 0.74 (0.55,0.99) 0.64 (0.47,0.86)
thal+bor + dex          0.90 (0.51,1.60) 0.86 (0.46,1.63) 0.75 (0.40,1.43) 0.65 (0.38,1.12)
bor + dex + pan           0.96 (0.66,1.42) 0.83 (0.55,1.23) 0.72 (0.60,0.88)
pom + dex            0.87 (0.62,1.20) 0.75 (0.50,1.11)
bor             0.87 (0.58,1.30)
  1. bev bevacizumab, bor bortezomib, carf carfilzomib, cyc cyclophosphamide, dara daratumumab, dex dexamethasone, elo elozumatab, IFN interferon alpha, ixa ixazomib, len lenalidomide, ob oblimersen, pan panobinostat, peri perifosine, PLD pegylated liposomal doxorubicin, pom pomalidomide, sil silituximab, thal thalidomide, vor vorinostat
  2. Significant results on the 95% level are marked in italic
Back to article page

BMC Medical Research Methodology

ISSN: 1471-2288

Contact us